Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korea To Cut Drug Prices By Up To 20% For Inferior Efficacy Results; More Cuts Expected

This article was originally published in PharmAsia News

Executive Summary

SEOUL - South Korea's Ministry of Health and Welfare will cut prices of 664 drugs by up to 20% after conducting a peer drug review of 2,398 products. The cuts will begin in July and will roll out over the next three years

You may also be interested in...



Korea Moves To Cut Drug Prices Of Seven Pharma Companies Over Rebates

SEOUL - In its first action following a warning in 2009 about drug rebates, the Korea Ministry of Health and Welfare is moving to cut market prices for 131 products manufactured by seven local Korean pharma companies by as high as 20%

Korea To Charge Patients More For Drugs Dispensed At Largest Hospitals

SEOUL - South Korea's Ministry of Health and Welfare is moving to charge patients more for drugs when they visit large general hospitals for minor ailments in an effort to deter public preference away from large hospitals, which has overburdened the country's national medical insurance system.

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

WI964856

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel